Bioinformatics analysis of hippocalcin like 1 expression and clinical prognosis in primary central nervous system lymphoma

doi:10.3969/j.issn.1006-7795.2023.05.004

Abstract

Abstract: Objective To infer the role of HPCAL1 in primary central nervous system lymphoma (PCNSL) based on bioinformatics analysis of the expression level and clinical significance of hippocalcin like 1 (HPCAL1) in PCNSL. Methods The expression data and clinical information of 7 PCNSL tissues and 7 normal brain tissues were downloaded from the GSE25297 dataset in the Gene Expression Omnibus (GEO) database to plot the receiver operating characteristic (ROC) curve of diagnostic value of HPCAL1 expression level. The expression data and clinical information of 34 PCNSL patients were downloaded from the GSE34771 dataset, and divided into two groups with high and low expression according to the median HPCAL1 expression level, and the survival curves of the high and low expression groups, the multivariate prognostic analysis of HPCAL1 expression and clinical information, the volcano map and heat map of differentially expressed genes in the high-low expression group. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis of differentially expressed genes, and the protein interaction network (PPI) analysis of the first 20 up-regulated and down-regulated differentially expressed genes were mapped. Results The expression of HPCAL1 is an independent prognostic factor and can be used as a basis for whether there is a disease or not. Compared with the HPCAL1 low-expression group, the high-expression group showed a longer overall survival. Through GO analysis, differential genes mainly focus on molecular functions such as maintaining cell homeostasis, promoting cell differentiation, inhibiting cell infinite proliferation and migration, and inhibiting transmission of nerve synapses. According to KEGG pathway analysis, differential genes were mainly concentrated in immune-related pathways such as cytokine-cytokine receptor interaction, lysosome, phagosome, and inflammation, and functional pathways such as Rap1 signaling pathway, extracellular matrix receptor interaction, and metabolic pathway. Conclusions Compared with the HPCAL1 low-expression group, the high-expression group showed a better prognosis. According to the expression level of HPCAL1, PCNSL patients can be intervened, and it is necessary to use HPCAL1 gene as a candidate biomarker for PCNSL.

Key words: hippocalcin like 1, primary central nervous system lymphoma, biomarker

CLC Number:

R739.4

Yu Jianyu, Zheng Yi, Li Wenbin. Bioinformatics analysis of hippocalcin like 1 expression and clinical prognosis in primary central nervous system lymphoma[J]. Journal of Capital Medical University, 2023, 44(5): 724-732.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2023.05.004

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2023/V44/I5/724

References

［1］Grommes C, Rubenstein J L, DeAngelis L, et al. Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma［J］. Neuro Oncol, 2019, 21(3):296-305.
［2］Mendez J S, Ostrom Q T, Gittleman H, et al. The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades［J］. Neuro Oncol, 2018, 20(5):687-694.
［3］Baraniskin A, Schroers R. Liquid biopsy and other non-invasive diagnostic measures in PCNSL［J］. Cancers (Basel), 2021, 13(11):2665.
［4］Villano J L, Koshy M, Shaikh H, et al. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma［J］. Br J Cancer, 2011, 105(9):1414-1418.
［5］Shiels M S, Pfeiffer R M, Besson C, et al. Trends in primary central nervous system lymphoma incidence and survival in the U.S［J］. Br J Haematol, 2016, 174(3):417-424.
［6］Calimeri T, Steffanoni S, Gagliardi F, et al. How we treat primary central nervous system lymphoma［J］. ESMO Open, 2021, 6(4):100213.
［7］Chen X, Song X, Li J, et al. Identification of HPCAL1 as a specific autophagy receptor involved in ferroptosis［J］. Autophagy, 2023, 19(1):54-74.
［8］Chen T, Yuan Z, Lei Z, et al. Hippocalcin-like 1 blunts liver lipid metabolism to suppress tumorigenesis via directly targeting RUVBL1-mTOR signaling［J］. Theranostics, 2022, 12(17):7450-7464.
［9］Wang X, Xie X, Zhang Y, et al. Hippocalcin-like 1 is a key regulator of LDHA activation that promotes the growth of non-small cell lung carcinoma［J］. Cell Oncol (Dordr), 2022, 45(1):179-191.
［10］Öner D, Ghosh M, Coorens R, et al. Induction and recovery of CpG site specific methylation changes in human bronchial cells after long-term exposure to carbon nanotubes and asbestos［J］. Environ Int, 2020, 137:105530.
［11］Braunewell K H, Klein-Szanto A J. Visinin-like proteins (VSNLs): interaction partners and emerging functions in signal transduction of a subfamily of neuronal Ca²⁺ -sensor proteins［J］. Cell Tissue Res, 2009, 335(2):301-316.
［12］Wang W, Zhong Q, Teng L, et al. Mutations that disrupt PHOXB interaction with the neuronal calcium sensor HPCAL1 impede cellular differentiation in neuroblastoma［J］. Oncogene, 2014, 33(25):3316-3324.
［13］Zhang Y, Liu Y, Duan J, et al. Hippocalcin-like 1 suppresses hepatocellular carcinoma progression by promoting p21(Waf/Cip1) stabilization by activating the ERK1/2-MAPK pathway［J］. Hepatology, 2016, 63(3):880-897.
［14］Zhang D, Liu X, Xu X, et al. HPCAL1 promotes glioblastoma proliferation via activation of Wnt/β-catenin signalling pathway［J］. J Cell Mol Med, 2019, 23(5):3108-3117.
［15］Ma M, Zeng G, Li J, et al. Expressional and prognostic value of HPCAL1 in cholangiocarcinoma via integrated bioinformatics analyses and experiments［J］. Cancer Med, 2023, 12(1):824-836.
［16］Siegel R L, Miller K D, Jemal A. Cancer statistics, 2015［J］. CA Cancer J Clin, 2015, 65(1):5-29.
［17］Hong J T, Son D J, Lee C K, et al. Interleukin 32, inflammation and cancer［J］. Pharmacol Ther, 2017, 174:127-137.
［18］Xu M, Wang Y, Xia R, et al. Role of the CCL2-CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting［J］. Cell Prolif, 2021, 54(10):e13115.
［19］Lee H, Park B C, Soon Kang J, et al. MAM domain containing 2 is a potential breast cancer biomarker that exhibits tumour-suppressive activity［J］. Cell Prolif, 2020, 53(9):e12883.
［20］Zois C E, Hendriks A M, Haider S, et al. Liver glycogen phosphorylase is upregulated in glioblastoma and provides a metabolic vulnerability to high dose radiation［J］. Cell Death Dis, 2022, 13(6):573.
［21］Yang J Y, Deng X Y, Li Y S, et al. Structure of Schlafen13 reveals a new class of tRNA/rRNA- targeting RNase engaged in translational control［J］. Nat Commun, 2018, 9(1):1165.
［22］Kim K, Park S, Park S Y, et al. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer［J］. Genome Med, 2020, 12(1):22.
［23］Park D J, Sung P S, Kim J H, et al. EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1［J］. J Immunother Cancer, 2020, 8(1):e000301.